LDN-193189: A selective inhibitor of bone morphogenetic protein (BMP) type I receptors (ALK-2 and ALK-3). Only weakly inhibits ALK-4,-5, and -7. 4-[6-(4-Piperazin-1-yl-phenyl)-pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline
Ref: Cuny, G.D., et al. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett 18: 4388-92, 2008.
Purity: Greater than 98% as determined by LC/MS analysis.